Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$12.75 USD
+1.04 (8.88%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $12.60 -0.15 (-1.18%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Cassava Sciences, Inc. [SAVA]
Reports for Purchase
Showing records 41 - 60 ( 127 total )
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
New Data Show Functional Interaction Between Simufilam, FLNA and Somatostatin Receptors; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 41123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 4123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 32123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Early 2023 Winds Favor Positive Progress With Simufilam; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 3123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 22123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 21123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 2123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Simufilam Open-Label, One-Year Phase 2 Results Point to Cognitive Function Improvement; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 12123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 11123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 1123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 122122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 121122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 12122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Raises $50M, When Cash Balance Sits at Over $174M - Lowering Price Target to $11, Maintain SELL
Provider: Univest Securities, LLC
Analyst: Research Department